Novavax, VaxInnate Receive BARDA Funds For Recombinant Flu Vaccine Development
This article was originally published in The Pink Sheet Daily
New processes would speed vaccine production and could improve on efficacy.
You may also be interested in...
Deals Of The Week: Express Scripts/Walgreens, Par/TPG, Amicus/GSK
Following the clinical trial failure of cancer candidate saridegib, Infinity takes back partnered assets from Purdue and plans to go it alone in the PI3K space.
Cell-Based Vaccine Development Gives Protein Sciences The Chills; Challenges Include Getting Advisory Committees To Accept FDA Decisions
Developing a new class of medical products takes creativity and perseverance by both sponsors and regulators, but as Protein Sciences' experience shows, bringing advisory committees up to speed on novel technologies can be just as important and challenging
Chick Eggs Cannot Yield Enough Vaccine For Pandemic: NYAS Swine Flu Mtg.
If preparation for a possible pandemic is ever going to be sufficient, drug makers need to push for FDA approval of adjuvants and novel technologies in which influenza vaccines can be created, according to a panel of experts